<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910214-0031</DOCNO><DOCID>910214-0031.</DOCID><HL>   Business Brief -- Alfin Inc.:   Anti-Aging Cream Lawsuit   Will Be Settled by Firm</HL><DATE>02/14/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C13</SO><CO>   AFN</CO><IN>COSMETICS, PERSONAL CARE, OVER-THE-COUNTER REMEDIES (COS)ADVERTISING, MARKETING, PUBLIC RELATIONS (ADV)</IN><LP>   Alfin Inc., New York, agreed to a $1.5 million settlementof a five-year-old class action lawsuit related to itscontroversial Glycel anti-aging cream.   Under the settlement, Alfin, which sold the Glycelbusiness in 1987 and now focuses on fragrances, agreed to paycertain shareholders $750,000 in cash, and to issue 30,000shares of preferred stock with a face value of $750,000.</LP><TEXT>   The suit, filed in 1986, alleged that the company andcertain executives made false claims about the benefits ofthe cream, and by doing so inflated the company's marketvalue.   The settlement resolves not only this suit but two othersbrought by shareholders, said Kenneth Schacter, an attorneyfor Alfin. An attorney for the shareholders didn't returnphone calls.   Alfin said it believed the suit had no merit, but settledto avoid substantial legal expenses and time demands. It saidthe $750,000 cash portion of the settlement was covered byinsurance.   Glycel, introduced in February 1986, was Alfin's mainskin-care product. It was endorsed by heart-transplantpioneer Christiaan Barnard, who Alfin claimed to be thedeveloper of the anti-aging ingredient in Glycel. For aperiod in 1986, the company's stock was actively traded.   But advertising claims prompted state and federalinquiries.</TEXT></DOC>